1. Home
  2. TNGX vs IHRT Comparison

TNGX vs IHRT Comparison

Compare TNGX & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • IHRT
  • Stock Information
  • Founded
  • TNGX 2014
  • IHRT 1974
  • Country
  • TNGX United States
  • IHRT United States
  • Employees
  • TNGX N/A
  • IHRT N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • IHRT Broadcasting
  • Sector
  • TNGX Health Care
  • IHRT Consumer Discretionary
  • Exchange
  • TNGX Nasdaq
  • IHRT Nasdaq
  • Market Cap
  • TNGX 351.2M
  • IHRT 193.4M
  • IPO Year
  • TNGX N/A
  • IHRT 2019
  • Fundamental
  • Price
  • TNGX $5.63
  • IHRT $2.05
  • Analyst Decision
  • TNGX Strong Buy
  • IHRT Buy
  • Analyst Count
  • TNGX 6
  • IHRT 3
  • Target Price
  • TNGX $12.20
  • IHRT $2.92
  • AVG Volume (30 Days)
  • TNGX 3.4M
  • IHRT 940.3K
  • Earning Date
  • TNGX 08-06-2025
  • IHRT 08-07-2025
  • Dividend Yield
  • TNGX N/A
  • IHRT N/A
  • EPS Growth
  • TNGX N/A
  • IHRT N/A
  • EPS
  • TNGX N/A
  • IHRT N/A
  • Revenue
  • TNGX $40,990,000.00
  • IHRT $3,862,595,000.00
  • Revenue This Year
  • TNGX N/A
  • IHRT N/A
  • Revenue Next Year
  • TNGX N/A
  • IHRT $5.89
  • P/E Ratio
  • TNGX N/A
  • IHRT N/A
  • Revenue Growth
  • TNGX 10.09
  • IHRT 3.31
  • 52 Week Low
  • TNGX $1.03
  • IHRT $0.95
  • 52 Week High
  • TNGX $12.02
  • IHRT $2.84
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 77.32
  • IHRT 70.79
  • Support Level
  • TNGX $4.80
  • IHRT $1.64
  • Resistance Level
  • TNGX $5.63
  • IHRT $1.95
  • Average True Range (ATR)
  • TNGX 0.52
  • IHRT 0.15
  • MACD
  • TNGX -0.03
  • IHRT 0.01
  • Stochastic Oscillator
  • TNGX 83.33
  • IHRT 80.81

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About IHRT iHeartMedia Inc.

iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

Share on Social Networks: